October 28, 2021
A New Jersey federal judge has dismissed an antitrust complaint accusing a Johnson & Johnson unit of launching sham patent litigation in order to delay generic competition from its blockbuster prostate cancer drug Zytiga, reasoning that the patent lawsuit at issue had merit.